Large-scale SPPS capacity in Braine-l’Alleud starts production

Media release

Large-scale SPPS capacity in Braine-l’Alleud starts production

Baar, 16 December 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the start of production with the new large-scale SPPS capacity at its manufacturing site in Braine-l’Alleud, Belgium.

Following the completion of construction and thorough testing, PolyPeptide commissioned its new solid-phase peptide synthesis (SPPS) capacity in Braine l’Alleud and started production, with the ramp-up planned throughout 2025. The capacity supports the multi-year commercial agreement announced previously in December 2022. The agreement has an annual order value of around EUR 100 million after the ramp-up phase.

To ensure high productivity, the new facility combines PolyPeptide’s proprietary manufacturing technology with an integrated engineering design and advanced automation and process control. Closed material flows and reduced solvent consumption contribute to improved sustainability.

Over the last three years, PolyPeptide invested around EUR 100 million into the new capacity. Its start of production is consistent with the guidance for 2024, and the mid-term outlook communicated by PolyPeptide on 13 August 2024.

Juan José González, CEO of PolyPeptide: “This project is the largest single investment in PolyPeptide’s 70-year history. The start of production is the result of the successful collaboration with our GLP-1 customer over several years. In parallel to the ramp-up ahead of us, we are pursuing our growth strategy with further GLP-1 capacity investments that combine innovative manufacturing technologies with the potential of modularity.”

 

Contact

PolyPeptide Group AG

Michael Stäheli

Head of Investor Relations & Corporate Communications

michael.staeheli@polypeptide.com

T: +41 43 502 0580

 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.

For more information, please visit polypeptide.com.  

@PolyPeptide – follow us on LinkedIn

Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. In particular, the statements related to the guidance for 2024 and mid-term outlook constitute forward-looking statements and are not guarantees of future financial performance. The Group’s actual results of operations could deviate materially from those set forth in the guidance for 2024 and mid-term outlook. As such, investors should not place undue reliance on the statements related to the guidance for 2024 and mid-term outlook. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.